Arecor Therapeutics PLC ARECOR STRENGTHENS COLLABORATION WITH PARTNER (7899P)

TIDMAREC

RNS Number : 7899P

Arecor Therapeutics PLC

14 February 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT

   -      Eighth new technology partnership with major pharmaceutical and biotech companies since IPO

Cambridge, UK, 14 February 2023 : Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022.

Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat(TM), to develop improved, stable, high concentration, liquid formulations of its proprietary product. The partner company will fund the initial development work and have the option to acquire the rights to the new proprietary formulations and associated intellectual property under a technology licensing model. This agreement follows the first agreement with the partner company, announced in June 2022.

Sarah Howell, Chief Executive Officer of Arecor, said: "The expansion of this important collaboration with a leading pharmaceutical company clearly demonstrates Arecor's expertise and the adaptability of our Arestat (TM) platform. This is the eighth new technology partnership with major pharmaceutical and biotech companies since Arecor's IPO in June 2021, which shows the need for our technology among leading pharmaceutical companies developing innovative products.

"This is key to the positive impact we can bring to our partners' development programmes, not only providing upside potential to Arecor from future licensing opportunities, but also further cementing our reputation within the industry as the go-to partner for challenging and complex formulation expertise."

-ENDS-

For more information, please contact:

 
Arecor Therapeutics plc                   www.arecor.com 
Dr Sarah Howell, Chief Executive Officer  Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
Susan Lowther, Chief Financial Officer    Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
Mo Noonan, Communications                 Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
Panmure Gordon (UK) Limited (NOMAD        Tel: +44 (0) 20 7886 2500 
 and Broker) 
 Freddy Crossley, Emma Earl (Corporate 
 Finance) 
 Rupert Dearden (Corporate Broking) 
 
Consilium Strategic Communications 
Chris Gardner, David Daley, Lindsey       Tel: +44 (0) 20 3709 5700 
 Neville                                   Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRDGGDDXDBDGXX

(END) Dow Jones Newswires

February 14, 2023 02:10 ET (07:10 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024